A new study by University of Kentucky Markey Cancer Center researchers suggests that targeting a key enzyme and its associated metabolic programming may lead to novel drug development to treat lung cancer.
Published in the Journal of Clinical Investigation, the study collected metabolic data directly from more than 120 human lung cancer patients. UK’s Center for Environmental and Systems Biochemistry (CESB) researchers Teresa Fan, Andrew Lane, and Richard Higashi led the study, with work done at both UK and the University of Louisville.
